atrial fibrillation

Mitochondrial Calcium Deficit Links Structural Remodeling to Atrial Fibrillation — and an Old Cholesterol Drug, Ezetimibe, Shows Unexpected Anti‑AF Potential

By MedXY 11/05/2025

New human tissue and cellular data implicate impaired mitochondrial Ca2+ uptake, structural uncoupling of sarcoplasmic reticulum–mitochondria contacts, and oxidative stress in atrial fibrillation (AF); ezetimibe restored mitochondrial Ca2+ handling and reduced AF burden in exploratory analyses.

Cardiology news Public Health

Active Monitoring for Atrial Fibrillation (AMALFI): Advancing Long-Term Remote Screening to Reduce Stroke Risk

By MedXY 10/21/2025

The AMALFI trial evaluates remote screening for asymptomatic atrial fibrillation in older adults to improve detection, anticoagulation use, and reduce stroke risk, with findings pending follow-up at 2.5 and 5 years.

Cardiology news Public Health

Remote ECG Patch Screening for Asymptomatic Atrial Fibrillation: Insights from the AMALFI Trial

By MedXY 10/21/2025

The AMALFI trial demonstrates that remote, mail-based 14-day ECG patch screening modestly increases long-term atrial fibrillation detection and anticoagulation use in older adults at stroke risk, with no observed reduction in stroke at 2.5 years.

Cardiology news

Reevaluating New-Onset Atrial Fibrillation After CABG: Insights from Long-Term Continuous Monitoring

By MedXY 10/10/2025

A multicenter prospective study reveals a higher incidence but very low burden of new-onset atrial fibrillation post-CABG, challenging current anticoagulation guidelines.

Clinical Updates news

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

By MedXY 09/27/2025

This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research.

Cardiology Nephrology

Abelacimab Shows Consistent Bleeding Safety Across Kidney Function in Atrial Fibrillation: Insights from the AZALEA-TIMI 71 Trial

By MedXY 09/27/2025

This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise for those with chronic kidney disease.

Cardiology Clinical Updates news Specialties

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY 09/22/2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Cardiology Specialties

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

By MedXY 09/11/2025

This secondary analysis of the CABANA trial reveals catheter ablation significantly benefits AF patients with fewer than three nonmodifiable recurrence risk factors, underscoring the potential for personalized treatment strategies.

Cardiology Diabetes & Endocrinology news Specialties

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 09/10/2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Cardiology news Pathology & Lab Medicine

Serum Carboxymethyl-Lysine and Its Prospective Associations with Heart Failure and Atrial Fibrillation in Older Adults: Insights from the Cardiovascular Health Study

By MedXY 09/08/2025

Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.

Clinical Updates news

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation

By MedXY 09/06/2025

A large randomized study found that biomarker-based ABC-AF risk score-guided therapy did not improve stroke or death outcomes versus usual care in atrial fibrillation, highlighting the need for rigorous prospective validation of precision medicine tools before clinical adoption.

Cardiology news Pathology & Lab Medicine Specialties

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial

By MedXY 09/06/2025

A biomarker-based ABC-AF risk score-guided treatment did not improve stroke or death outcomes versus standard care in atrial fibrillation, underscoring the need for prospective validation of precision medicine tools before clinical implementation.

Cardiology Clinical Updates news Specialties

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

By MedXY 09/02/2025

The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer adverse events.

Cardiology Specialties

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

By MedXY 09/01/2025

The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies in selected patients.

Cardiology news Radiology Specialties

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

By MedXY 08/30/2025

This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assessment.

Cardiology Specialties

Dynamic Triglyceride-Glucose Index Trajectories as Predictors of Mortality in Critically Ill Patients with Atrial Fibrillation

By MedXY 08/21/2025

A retrospective study shows high and fluctuating triglyceride-glucose (TyG) index trajectories predict increased short- and long-term mortality in ICU patients with atrial fibrillation, highlighting TyG dynamics as a valuable prognostic biomarker.

Cardiology news Specialties

Dynamic Triglyceride-Glucose Index Trajectories Predict Mortality in Critically Ill Atrial Fibrillation Patients

By MedXY 08/21/2025

This study reveals that fluctuating high triglyceride-glucose (TyG) index trajectories in critically ill atrial fibrillation patients significantly predict increased all-cause mortality up to one year post-ICU admission, offering a novel prognostic tool for risk stratification.

Cardiology Specialties

Optimizing Anticoagulant Therapy in Frail Elderly AF Patients: Insights from the COMBINE-AF Substudy

By MedXY 08/17/2025

Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remained similar.

Cardiology Specialties

Marshall-Plan Ablation Strategy Versus Pulmonary Vein Isolation in Persistent AF

By MedXY 08/17/2025

This study compares the effectiveness of the Marshall-Plan ablation strategy against pulmonary vein isolation for treating persistent atrial fibrillation.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.